MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$7,164,507
EPS
-$0.99
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-04-30
2025-10-31
2025-07-31
Research, development, and clinical trial expenses, net
5,966,673
6,683,643
5,317,669.5*
General and administrative expenses
1,654,121
1,639,300
1,483,531.25*
Total operating expenses
7,620,794
8,322,943
6,801,200.75
Operating loss
-7,620,794
-8,322,943
-6,801,200.75*
Financial (income) expenses, net
186,970
158,646
28,627.75*
Change in fair value of the warrant liability
-123,242
69,201
-189,591*
Unrealized gain on investment
137,830
-
-
Share of loss on equity investment
-64,303
-44,830
-56,053*
Net loss for the period
-7,237,055
-8,278,328
-6,639,035*
Net loss attributable to non-controlling interest
-72,548
-80,763
-61,068.25*
Net loss and comprehensive loss for the period attributable to briacell
-7,164,507
-8,197,565
-6,577,966.75
Basic EPS
-0.99
-4.35
-15.547
Diluted EPS
-0.99
-4.35
-15.547
Basic Average Shares
7,250,487
1,883,906
423,114
Diluted Average Shares
7,250,487
1,883,906
423,114
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss and
comprehensive loss for the...
-$7,164,507
Net loss
attributable to...
-$72,548
Net loss for the
period
-$7,237,055
Financial (income)
expenses, net
$186,970
Unrealized gain on
investment
$137,830
Change in fair value of
the warrant...
-$123,242
Operating loss
-$7,620,794
Share of loss on equity
investment
-$64,303
Total operating
expenses
$7,620,794
Research, development,
and clinical trial...
$5,966,673
General and
administrative expenses
$1,654,121
Buy us a coffee
BriaCell Therapeutics Corp. (BCTX)
BriaCell Therapeutics Corp. (BCTX)